ABSTRACT GUIDELINES



Abstracts must be submitted electronically via the conference website. No faxed or mailed abstracts will be accepted. There are no exceptions to the deadline as the review period ensues immediately after the submission site closes.


Official Language
All presentations at APASL Annual Meeting 2018 will be in English.

 

Abstract Title
There is a limit of 300 characters, including spaces, for the title of an abstract.


Authors

Please list all authors with their affiliations (institution, city and country).


Authorship

Credit for authorship requires substantial contributions to the conception and design; or the acquisition, analysis, or interpretation of the data, final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.


Abstract Body
There is a limit of 3000 characters, including spaces, for the body of abstract submissions. Abstract titles, author names, author institutions, and information in tables and images do not count toward the 3000 character limit. Abstract text for original article should include 1) background/aims, 2) methods, 3) results and 4) conclusions. For case report, it should include introduction and case description. Do not include references and key words in the abstract.


Tables and Figures

A maximum of 2 images can be included per abstract. The maximum file size of each graph/image is 2M. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. Graphs and images may be uploaded in JPG, PNG and GIF format only. When including a table it is recommended to save the table as an image and then upload it in to the abstract.


Format
Use the abbreviation in parentheses after the full word the first time it appears.
To avoid character corruption, please use only Times New Roman font.
Font size should be 10.


Editing A Submitted Abstract
Authors may edit submitted abstracts until the submissions deadline. Abstract submitters should log into their registration account to make any edits.


Submission Categories
Authors must select a submissions category when submitting their abstract. Please find the below Full List Of Abstract Submission Categories:

Acute Liver Failure and Artificial Liver Support-Clinical
• CA-01 Acute Liver Failure and Artificial Liver Support-Clinical
Acute Liver Failure and Artificial Liver Support- Basic
BA-01 Acute Liver Failure and Artificial Liver Support-Basic Science
Alcoholic Liver Disease-Clinical
• CAL-01 Alcoholic Liver Disease: Clinical and Therapeutic
Alcoholic Liver Disease-Basic
• BAL-01 Alcoholic Liver Disease: Experimental
Hepatitis B and D-Clinical
• CB-01 Diagnostics, Epidemiology, Prevention, Natural History
• CB-02 Therapeutics: New and Approved
Hepatitis B and D-Basic
• BB-01 Virology, Pathogenesis, and Immunology
Biliary and pancreatic Neoplasia other than Liver cancer-Clinical
• CBN-01 Diagnostics and Liver Imaging of biliary and pancreatic neoplasia
• CBN-02 Prognosis : biliary and pancreatic neoplasia
• CBN-03 Surgery and Loco-Regional Therapy for biliary and pancreatic neoplasia
• CBN-04 Targetted and systemic therapies for biliary and pancreatic neoplasia
Biliary and pancreatic Neoplasia other than Liver cancer-Basic
• BBN-01 Experimental carcinogenesis of biliary and pancreatic neoplasia
Hepatitis C-Clinical
• CC-01 Diagnostics, Epidemiology, Natural History
• CC-02 Therapeutics: Preclinical and Early Clinical Development
• CC-03 Therapeutics: New Agents (not approved, phase 2-3)
• CC-04 Therapeutics: Approved Agents
Hepatitis C-Basic
• BC-01 Virology, Pathogenesis, and Immunology
Cholestatic and Autoimmune Liver Diseases-Clinical
• CCA-01 PBC/PSC and Other Cholestatic Disease: Clinical and Therapeutics
• CCA-02 Autoimmune Liver Disease: Clinical and Therapeutics
Cholestatic and Autoimmune Liver Diseases-Basic
• BCA-01 Transport, Bilirubin, Cholesterol, Lipids and Bile Salts, Cholangiocyte    Biology and Experimental Cholestasis
• BCA-02 Autoimmune Liver Disease:Experimental
Drug Induced Liver Injury-Clinical
• CD-01 Predictors of Drug Toxicity and Therapy
Drug Induced Liver Injury-Basic
• BD-01 Pathogenesis and Mechanisms
• BD-02 Drug Metabolism, and Toxicity
Hepatitis A and E-Clinical
• CE-01 Hepatitis A and E- Clinical and Therapeutic
Hepatitis A and E-Basic
• BE-01 Hepatitis A and Experimental
Liver Fibrogenesis and Non-Parenchymal Cell Biology-Clinical
• BF-01 Imaging and Noninvasive Markers of Liver Fibrosis 
• BF-02 Clinical and Translational Fibrosis Research and Therapy
Liver Fibrogenesis and Non-Parenchymal Cell Biology-Basic
• BF-01 Basic Fibrosis Research and Stellate Cell Biology
Genetic and Metabolic Disease-Clinical
• CG-01 Hemochromatosis, Wilson Disease, ∝-1 Antitrypsin Deficiency-Clinical
• CG-02 Other genetic and metabolic disorders-Clinical
Genetic and Metabolic Disease-Basic
• BG-01 Hemochromatosis, Wilson Disease, ∝-1 Antitrypsin Deficiency-Experimental
• BG-02 Other genetic and metabolic disorders-Experimental
Inflammation and Immunology-Basic
• BI-01 Animal Models
• BI-02 Innate Immunity
• BI-03 Adaptive Immunity
• BI-04 Mechanisms of Injury and others
Liver Cancer-Clinical
• CLC-01 Diagnostics and Liver Imaging of hepatocellular carcinoma
• CLC-02 Prognosis : Hepatocellular Carcinoma
• CLC-03 Liver transplantation, Surgery and Loco-Regional Therapy for    Hepatocellular Carcinoma
• CLC-04 Targetted and systemic therapies for Hepatocellular Carcinoma
Liver Cancer -Basic
• BLC-01 Experimental Hepatocarcinogenesis
Liver Transplantation and Liver Surgery-Clinical
• CLTS-01 Donor and Allocation Issues; Living Donor and Split Liver Transplantation,
• CLTS-02 Immunosuppression, Outcomes, Complications of liver transplantation
• CLTS-03 Viral Hepatitis and liver transplantation 
• CLTS-04 Hepatobiliary Surgery
Liver Transplantation and Liver Surgery-Basic
• BLTS-01 Cellular Immunobiology, Preservation and Cell Transplantation, Experimental
Molecular and Cellular  Biology and Stem Cell Therapy -Basic
• BM-01 Cell Structure; Function; Signal Transduction, Nuclear Receptors
• BM-02 Gene Expression and Gene Therapy
• BM-03 Stem Cell Biology- Basic Sciences
• BM-04 Stem cell therapy: Clinical
Portal Hypertension and Other Complications of Cirrhosis-Clinical
• CP-01 Ascites, Renal Dysfunction and Hepatorenal Syndrome
• CP-02 Varices and Bleeding
• CP-03 Encephalopathy and Infections and Other Complications
• C-P04 Acute on Chronic Liver Failure
Portal Hypertension and Other Complications of Cirrhosis including ACLF-Basic
• BP-01 Experimental
Pediatric Hepatology-Clinical
• CPD-01 Biliary Atresia and Cholestasis
• CPD-02 Viral and Autoimmune Hepatitis
• CPD-03 Metabolic and Genetic Diseases
• CPD-04 Pediatric Liver Transplantation
Pediatric Hepatology-Basic
• BPD-01 Pediatric Liver Disease - Basic Science
Public Health Services Research
• CPH-01 Health Care Delivery/Access/Quality
• CPH-02 Health Economics and Cost-Effectiveness and Economics of Care
• CPH-03 Other public health issues
Miscellaneous-Clinical
• CM-01 Miscellaneous issues-Clinical
Miscellaneous-Basic
• BM-01: Miscellaneous issues-Experimental
NAFLD / NASH - Clinical
• CNA - 01
NAFLD / NASH - Basic
• BNA - 01
• HCR - 01 Hepatobiliary clinical vigenettes / case reports
• CCH - 01 Critical care hepatology

 

For any abstract query, please contact:
Mr. Aditya Chaudhary

Mob.: +91-8802552236

Contact Us

Conference Secretariat


  • Address:
    Institute of Liver and Biliary Sciences
    D-1 Vasant Kunj, New Delhi - 110070, India
    Email: info@apasl2018.in
    Website: www.apasl2018.in


    Contact Person:
    Dr. Barjesh C Sharma
    President
    Mob.: +91-9540951000

    Dr. Manoj K Sharma
    Organizing Secretary
    Mob.: +91-9313416555

    Dr. Rakhi Maiwall
    Treasurer
    Mob.: +91-8750343085

Conference Manager


  • Address:
    Summit - Alpcord Network
    1201, 12th Floor, New Delhi House, 27,
    Barakhamba Road, New Delhi - 110001
    Phone: +91 11 49104010
    Website: www.alpcord.com

  • Contact Person:
    Mr. Devender K Saini
    Mob.: +91-9910894884

    Mr. Aditya Chaudhary
    Mob.: +91-8802552236